Boehringer Ingelheim received accelerated FDA approval for Hernexeos (zongertinib), the first oral HER2-targeted therapy authorized for patients with non-small-cell lung cancer harboring HER2 tyrosine kinase domain mutations. This approval offers a new treatment option for patients with unresectable or previously treated disease and pits Hernexeos against AstraZeneca’s Enhertu in this niche lung cancer segment. Thermo Fisher’s Oncomine Dx Target Test was approved simultaneously as a companion diagnostic.